摘要
目的:探究血清糖类抗原(CA)153、CA125、癌胚抗原(CEA)联合检测在乳腺癌患者临床诊断中的效果。方法:选择2021年1月—2022年12月滨州市中心医院收治的乳腺癌患者81例、乳腺良性疾病患者55例以及健康女性体检者67例作为本次研究对象。研究对象均采用化学发光微粒子免疫分析技术进行诊断,对血清CA153、CA125及CEA的含量进行测定。比较三组研究对象CA153、CA125、CEA检测结果,三组研究对象CA153、CA125、CEA单项检测及联合检测阳性率,不同临床分期乳腺癌患者CA153、CA125、CEA检测结果。结果:乳腺癌组患者CA153、CA125以及CEA指标水平高于参照组及乳腺良性疾病组,差异有统计学意义(P<0.05)。乳腺癌组患者CA153、CA125、CEA单项检测及联合检测阳性率显著高于参照组及乳腺良性疾病组,差异有统计学意义(P<0.05)。Ⅲ期以及Ⅳ期乳腺癌患者的CA153、CA125、CEA水平高于Ⅰ期、Ⅱ期乳腺癌患者,差异有统计学意义(P<0.05)。结论:在乳腺癌患者临床诊断中,CA153、CA125以及CEA均属于肿瘤标志物检测方法,应用CA153、CA125、CEA联合检测方案,可提高检测阳性率,有助于明确乳腺癌分期,为临床诊断与治疗提供可靠依据。
Objective:To explore the effect of serum carbohydrate antigen(CA)153,CA125 and carcinoembryonic antigen(CEA)combined detection in the clinical diagnosis of breast cancer patients.Methods:A total of eighty-one patients with breast cancer,fifty-five patients with benign breast diseases and sixty-seven healthy women who underwent physical examination in Binzhou Central Hospital from January 2021 to December 2022 were selected as the subjects of this study.The subjects were diagnosed by chemiluminescent particle immunoassay,and the levels of serum CA153,CA125 and CEA were determined.The detection results of CA153,CA125 and CEA in the three groups were compared,the positive rates of single detection and combined detection of CA153,CA125 and CEA in the three groups,and the detection results of CA153,CA125 and CEA in breast cancer patients with different clinical stages were compared.Results:The levels of CA153,CA125 and CEA indexes in breast cancer group were higher than those in reference group and benign breast disease group,and the differences were statistically significant(P<0.05).The positive rates of CA153,CA125 and CEA in breast cancer group were significantly higher than those in reference group and benign breast disease group,and the difference was statistically significant(P<0.05).The levels of CA153,CA125 and CEA in stageⅢandⅣbreast cancer patients were higher than those in stageⅠandⅡbreast cancer patients,and the difference was statistically significant(P<0.05).Conclusion:In the clinical diagnosis of breast cancer patients,CA153,CA125 and CEA all belong to tumor marker detection methods.The application of the combined detection scheme of CA153,CA125 and CEA can improve the positive rate of detection,help to clarify the stage of breast cancer,and provide a reliable basis for clinical diagnosis and treatment.
作者
单新芳
Shan Xin-fang(Binzhou Central Hospital,Binzhou 251700,Shandong Province,China)
出处
《中外医药研究》
2023年第6期136-138,共3页
JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH
关键词
乳腺癌
糖类抗原153
糖类抗原125
癌胚抗原
Breast cancer
Carbohydrate antigen 153
Carbohydrate antigen 125
Carcinoembryonic antigen
